Ellen Tully

997 total citations
16 papers, 796 citations indexed

About

Ellen Tully is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Ellen Tully has authored 16 papers receiving a total of 796 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Cancer Research and 5 papers in Oncology. Recurrent topics in Ellen Tully's work include Cancer, Lipids, and Metabolism (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Peroxisome Proliferator-Activated Receptors (3 papers). Ellen Tully is often cited by papers focused on Cancer, Lipids, and Metabolism (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Peroxisome Proliferator-Activated Receptors (3 papers). Ellen Tully collaborates with scholars based in United States, South Korea and Japan. Ellen Tully's co-authors include Edward Gabrielson, Edward Gabrielson, Hajime Orita, Jonathan B. Coulter, Kathleen Wilsbach, Francis P. Kuhajda, Yunyue Wang, Bibo Yuan, Robert P. Wersto and Young Kyung Bae and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Cancer Research.

In The Last Decade

Ellen Tully

16 papers receiving 782 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ellen Tully United States 11 472 288 270 136 132 16 796
Danupon Nantajit United States 11 561 1.2× 345 1.2× 232 0.9× 118 0.9× 88 0.7× 20 928
Hefen Sun China 20 585 1.2× 329 1.1× 341 1.3× 157 1.2× 77 0.6× 44 995
Jiaqiang Dong China 17 780 1.7× 257 0.9× 427 1.6× 97 0.7× 85 0.6× 30 1.2k
Guangchun He China 15 478 1.0× 323 1.1× 297 1.1× 176 1.3× 44 0.3× 25 952
Mingde Zang China 14 457 1.0× 211 0.7× 206 0.8× 104 0.8× 45 0.3× 21 732
Ignacio Dolado Spain 11 695 1.5× 333 1.2× 170 0.6× 70 0.5× 90 0.7× 20 1.0k
Hisao Fukumoto Japan 17 587 1.2× 432 1.5× 129 0.5× 193 1.4× 58 0.4× 30 1.0k
Yong‐Chuan Wong Hong Kong 17 659 1.4× 272 0.9× 220 0.8× 136 1.0× 138 1.0× 27 945
Kay T. Yeung United States 10 557 1.2× 299 1.0× 264 1.0× 94 0.7× 69 0.5× 19 848
Can‐Can Zheng China 15 618 1.3× 217 0.8× 269 1.0× 90 0.7× 53 0.4× 22 888

Countries citing papers authored by Ellen Tully

Since Specialization
Citations

This map shows the geographic impact of Ellen Tully's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen Tully with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen Tully more than expected).

Fields of papers citing papers by Ellen Tully

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen Tully. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen Tully. The network helps show where Ellen Tully may publish in the future.

Co-authorship network of co-authors of Ellen Tully

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen Tully. A scholar is included among the top collaborators of Ellen Tully based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen Tully. Ellen Tully is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Tully, Ellen, Peng Huang, Philipp Oberdoerffer, et al.. (2023). Temozolomide Sensitizes ARID1A -Mutated Cancers to PARP Inhibitors. Cancer Research. 83(16). 2750–2762. 12 indexed citations
2.
Tully, Ellen, Santosh Kumar Bharti, Juhyung Woo, Zaver M. Bhujwalla, & Edward Gabrielson. (2021). Biguanide drugs enhance cytotoxic effects of cisplatin by depleting aspartate and NAD+ in sensitive cancer cells. Cancer Biology & Therapy. 22(10-12). 579–586. 5 indexed citations
3.
Fu, Yingli, Clifford R. Weiss, Dorota Kedziorek, et al.. (2019). Noninvasive Monitoring of Allogeneic Stem Cell Delivery with Dual-Modality Imaging-Visible Microcapsules in a Rabbit Model of Peripheral Arterial Disease. Stem Cells International. 2019. 1–10. 2 indexed citations
4.
Sugimoto, Kiichi, Tomoaki Ito, Juhyung Woo, et al.. (2018). Prognostic Impact of Phosphorylated Discoidin Domain Receptor-1 in Esophageal Cancer. Journal of Surgical Research. 235. 479–486. 8 indexed citations
5.
Singh, Anju, Ellen Tully, Juhyung Woo, et al.. (2018). Nrf2 signaling and autophagy are complementary in protecting breast cancer cells during glucose deprivation. Free Radical Biology and Medicine. 120. 407–413. 40 indexed citations
6.
Kumar, Dhiraj, Ala Lisok, Elyes Dahmane, et al.. (2018). Peptide-based PET quantifies target engagement of PD-L1 therapeutics. Journal of Clinical Investigation. 129(2). 616–630. 103 indexed citations
7.
Gniadek, Thomas J., Qing Kay Li, Ellen Tully, et al.. (2017). Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy. Modern Pathology. 30(4). 530–538. 84 indexed citations
8.
Tully, Ellen, et al.. (2011). Nuclear Factor-κB (NF-κB) Mediates a Protective Response in Cancer Cells Treated with Inhibitors of Fatty Acid Synthase. Journal of Biological Chemistry. 286(36). 31457–31465. 15 indexed citations
9.
Orita, Hajime, Jonathan B. Coulter, Ellen Tully, et al.. (2010). High levels of fatty acid synthase expression in esophageal cancers represent a potential target for therapy. Cancer Biology & Therapy. 10(6). 549–554. 25 indexed citations
10.
Orita, Hajime, Jonathan B. Coulter, Ellen Tully, Francis P. Kuhajda, & Edward Gabrielson. (2008). Inhibiting Fatty Acid Synthase for Chemoprevention of Chemically Induced Lung Tumors. Clinical Cancer Research. 14(8). 2458–2464. 76 indexed citations
11.
Coulter, Jonathan A., et al.. (2008). SF-077-4 Selective inhibition of fatty acid synthase for lung cancer treatment. 109(2). 283. 1 indexed citations
12.
Li, Dapeng, Hajime Orita, Jonathan B. Coulter, et al.. (2007). Coix seed extract, A commonly used treatment for cancer in china, inhibits NFκB and protein kinase C signaling. Cancer Biology & Therapy. 6(12). 2005–2011. 70 indexed citations
13.
Orita, Hajime, Jonathan B. Coulter, Ellen Tully, et al.. (2007). Selective Inhibition of Fatty Acid Synthase for Lung Cancer Treatment. Clinical Cancer Research. 13(23). 7139–7145. 96 indexed citations
14.
Xu, Yi, Juhyung Woo, Yunyue Wang, et al.. (2006). Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS et al.. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res 12: 405-410. 10 indexed citations
15.
Yuan, Bibo, Yi Xu, Yunyue Wang, et al.. (2006). Increased Expression of Mitotic Checkpoint Genes in Breast Cancer Cells with Chromosomal Instability. Clinical Cancer Research. 12(2). 405–410. 227 indexed citations
16.
Gabrielson, Edward, Ellen Tully, Amy Hacker, et al.. (2004). Induction of spermidine/spermine N1-acetyltransferase in breast cancer tissues treated with the polyamine analogue N1,N11-diethylnorspermine. Cancer Chemotherapy and Pharmacology. 54(2). 122–126. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026